Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A. Bardia, W. A. Messersmith, E. A. Kio, J. D. Berlin, L. Vahdat, G. A. Masters, R. Moroose, A. D. Santin, K. Kalinsky, V. Picozzi, J. O'Shaughnessy, J. E. Gray, T. Komiya, J. M. Lang, J. C. Chang, A. Starodub, D. M. Goldenberg, R. M. Sharkey, P. Maliakal, Q. HongW. A. Wegener, T. Goswami, A. J. Ocean
Dive into the research topics of 'Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial'. Together they form a unique fingerprint.